- Jefferies analyst raises price target for Scholar Rock to $65 from $57.
- Scholar Rock received U.S. Food and Drug Administration (FDA) approval for ISEMBYLD, a new treatment for spinal muscular atrophy (SMA).
- ISEMBYLD is the first muscle-targeted therapy for SMA, with a list price of $11,659 per single-use vial.
Scholar Rock (NASDAQ: SRRK) is a biopharmaceutical company focused on creating treatments for serious diseases that involve protein growth factors. The company's primary work centers on developing therapies for conditions like spinal muscular atrophy (SMA), a rare and severe neuromuscular disorder that causes progressive muscle weakness and loss of motor function.
Following recent developments, Jefferies analyst Amy Li raises the price target for Scholar Rock to $65, up from the previous $57. When this new target was announced on September 14, 2026, the stock was trading at $51.85. This updated forecast suggests a potential increase of about 25.36% from its price at the time.
This optimism is linked to a major company achievement. As announced by Business Wire, Scholar Rock received U.S. Food and Drug Administration (FDA) approval for its drug, ISEMBYLD. This treatment is for adults and children aged two and older with spinal muscular atrophy who are already on another type of therapy.
ISEMBYLD is the first muscle-targeted therapy approved to improve motor function in these patients. In recognition of this, the FDA also gave Scholar Rock a Rare Pediatric Disease Priority Review Voucher. As highlighted by Reuters, the company sets the list price for the new drug at $11,659 per single-use vial.
On the day of the analyst update, Scholar Rock stock trades at $51.85, with a daily range between $51.58 and $56.55. The company has a market capitalization of approximately $6.21 billion. Market capitalization is the total value of a company's shares and is calculated by multiplying the share price by the number of shares.
